Advances in immunotherapy for glioblastoma multiforme

Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor of the central nervous system and has a very poor prognosis. The current standard of care for patients with GBM involves surgical resection, radiotherapy, and chemotherapy. Unfortunately, conventional therapies hav...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 13; p. 944452
Main Authors Mahmoud, Ahmad Bakur, Ajina, Reham, Aref, Sarah, Darwish, Manar, Alsayb, May, Taher, Mustafa, AlSharif, Shaker A., Hashem, Anwar M., Alkayyal, Almohanad A.
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 12.10.2022
Subjects
CAR-T cells
checkpoint inhibitors
glioblastoma multiforme
glioma
Immunology
immunotherapy
oncolytic virotherapy
Online AccessGet full text

Cover

More Information
Summary:Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor of the central nervous system and has a very poor prognosis. The current standard of care for patients with GBM involves surgical resection, radiotherapy, and chemotherapy. Unfortunately, conventional therapies have not resulted in significant improvements in the survival outcomes of patients with GBM; therefore, the overall mortality rate remains high. Immunotherapy is a type of cancer treatment that helps the immune system to fight cancer and has shown success in different types of aggressive cancers. Recently, healthcare providers have been actively investigating various immunotherapeutic approaches to treat GBM. We reviewed the most promising immunotherapy candidates for glioblastoma that have achieved encouraging results in clinical trials, focusing on immune checkpoint inhibitors, oncolytic viruses, nonreplicating viral vectors, and chimeric antigen receptor (CAR) immunotherapies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Aiping Tong, Sichuan University, China
Reviewed by: Hu Jinyang, Three Gorges University College of Medicine, China; Rupsa Basu, Humane Genomics, United States
This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.944452